That is, the variant in enhancer ‘chr12:12713282–12727320’ would intervene LY-294002 sensitivity in prostate cancer patients through altering the regulation of LY-294002 perturbed gene: APOLD1. The gene discussed is APOLD1; the disease is prostate carcinoma.